NervGen Email Format

Biotechnology ResearchBritish Columbia, Canada11-50 Employees

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions. Its lead candidate, NVG-291, is delivered by subcutaneous administration and has been evaluated in the Phase 1b/2a CONNECT SCI trial in individuals with chronic SCI (1 to 10 years post-injury), where it demonstrated durable improvements in function, independence, and quality of life. The company is advancing NVG-300 as a next-generation candidate and is preparing for a Phase 3 trial in chronic SCI, while being based in Vancouver, British Columbia, and operating with a small to mid-sized team.

NervGen has regulatory designations for SCI, including FDA Fast Track and EMA Orphan Drug status. In April 2026, the company appointed Keith Vendola as Chief Financial Officer, reflecting ongoing governance activity and continued engagement with the broader scientific and investor communities through industry events.

Get verified NervGen emails free

Company overview Employee directory